About Huang Lian
Coptis (goldthread) owes nearly all of its clinical relevance to berberine, its primary alkaloid at roughly 5–9% of the rhizome by weight; berberine itself has solid RCT evidence for glycemic control and lipid lowering at 500–1500 mg/day. The rhizome also carries smaller amounts of coptisine, palmatine, and epiberberine, and as a whole herb it lacks comparable Western RCT data — it is used mostly in TCM formulas (e.g., Huang Lian Jie Du Tang). Scoring note: if a label lists both Coptis rhizome and berberine HCl, do not award independent points — they target the same mechanism (AMPK activation, gut microbiome shifts, intestinal glucose absorption). Drug interactions: berberine is a potent CYP3A4 and P-gp inhibitor — significant interaction risk with cyclosporine, statins, macrolides, and other substrates. Avoid in pregnancy (berberine crosses the placenta, linked to neonatal kernicterus risk) and in neonates.
What Huang Lian supports
- Berberine-driven mechanism for glycemic and lipid effects — but only at therapeutic doses
- Most products under-dose; clinical effect requires gram-scale rhizome or isolated berberine
How much Huang Lian to take
The RDA prevents deficiency. The effective range is what clinical trials used to actually move the outcome.
Effective
1000–6000
mg
Whole-rhizome dosing required to deliver clinically meaningful berberine (rhizome is ~5–9% berberine; berberine RCTs use 500–1500 mg/day, so ~6–15 g rhizome equivalent). Most products under-dose dramatically. If supplementing for berberine effects, isolated berberine HCl is the studied form.
Clinical evidence
Limited clinical evidence. Coptis-specific RCTs are rare; clinical relevance is borrowed from berberine literature (Lan et al. 2015 PMID 25498346 on glycemic outcomes). Whole-rhizome trials are mostly small and Chinese-language.
Reference